Back to Search
Start Over
[French national overview of the inclusion of environmental criteria in the public purchasing of health products (drugs and sterile medical devices)].
- Source :
-
Annales pharmaceutiques francaises [Ann Pharm Fr] 2022 Mar; Vol. 80 (2), pp. 216-226. Date of Electronic Publication: 2021 Jun 18. - Publication Year :
- 2022
-
Abstract
- Objectives: Healthcare products (HP) have a significant carbon footprint that must be included by regulation in the facility's purchasing policy. A national overview of the inclusion of environmental criteria (EC) in the public procurement (PP) of HP in hospitals has been carried out.<br />Methods: Thirty EC were identified in the literature. Two questionnaires were proposed: (i) for buyers that analyze the level of "importance" and "ease of application" for public tenders (PT), and (ii) for suppliers that declare their commitments and evidence.<br />Results: Six regional buyers and 28 suppliers participated. Buyers recognize the "importance" of sustainable development (SD) but are more reticent about the "applicability" of EC in PT. The environmental rating remains low: on average 4.38 (0.25-10.00) % of the total rating. Only 12 EC are integrated within some PT. Suppliers report a high and diversified commitment to SD: 18 suppliers sent 474 evidence. Buyers and suppliers converge on the optimization of primary packaging and the establishment of a minimum order or delivery group.<br />Conclusions: Since the efficiency of PP is inevitable, EC that combines SD and savings should be prioritized. The integration of additional EC, simple and easily documented, allowing cost containment for both suppliers and buyers, is possible to promote sustainable purchasing.<br /> (Copyright © 2021 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.)
Details
- Language :
- French
- ISSN :
- 0003-4509
- Volume :
- 80
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Annales pharmaceutiques francaises
- Publication Type :
- Academic Journal
- Accession number :
- 34153241
- Full Text :
- https://doi.org/10.1016/j.pharma.2021.06.005